Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer

ConclusionCombined use of CD47 and CD68 exhibited excellent performance in predicting survival of patients with NSCLC. CD47 was a potential therapeutic target for immune therapy of lung cancer.

Source: Journal of Cancer Research and Clinical Oncology - January 4, 2021 Category: Cancer & Oncology Source Type: research